Reversal of the malignant phenotype of ovarian cancer A2780 cells through transfection with wild-type PTEN gene

Cancer Letters

Volumn 271, Issue 2, 2008, Pages 205-214

  Wu, Huijuan ^a,b   Wang, Shixuan ^a   Weng, Danghui ^a   Xing, Hui ^a   Song, Xiaohong ^a   Zhu, Tao ^a   Xia, Xi ^a   Weng, Yanjie ^a   Xu, Gang ^a   Meng, Li ^a   Zhou, Jianfeng ^a   Ma, Ding ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Invasion; Migration; Ovarian cancer; Proliferation; PTEN

Indexed keywords

PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CANCER; PHENOTYPE; PLASMID; PRIORITY JOURNAL; UPREGULATION; WILD TYPE;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; OVARIAN NEOPLASMS; PHENOTYPE; PLASMIDS; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 53249143988     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.06.018     Document Type: Article

References (34)

1. Naora H., and Montell D.J. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat. Rev. Cancer 5 (2005) 355-366
2. Ma X., Wang S., Zhou J., Xing H., Xu G., Wang B., Chen G., Lu Y.P., and Ma D. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. Oncol. Rep. 14 (2005) 275-279
3. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., and Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
4. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., and Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
5. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H., and Tavtigian S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15 (1997) 356-362
6. Li D.M., and Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 57 (1997) 2124-2129
7. Hafizi S., Ibraimi F., and Dahlback B. C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration. FASEB J. 19 (2005) 971-973
8. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
9. Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., and Yamada K.M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280 (1998) 1614-1617
10. Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., and Parsons R. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57 (1997) 4183-4186
11. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F., and Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57 (1997) 3660-3663
12. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., Jen J., Isaacs W.B., Bova G.S., and Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57 (1997) 4997-5000
13. Rhei E., Kang L., Bogomolniy F., Federici M.G., Borgen P.I., and Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 57 (1997) 3657-3659
14. Tashiro H., Blazes M.S., Wu R., Cho K.R., Bose S., Wang S.I., Li J., Parsons R., and Ellenson L.H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57 (1997) 3935-3940
15. Schondorf T., Gohring U.J., Roth G., Middel I., Becker M., Moser N., Valter M.M., and Hoopmann M. Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients. Eur. J. Clin. Invest. 33 (2003) 256-260
16. Meng Q., Xia C., Fang J., Rojanasakul Y., and Jiang B.H. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell. Signal. 18 (2006) 2262-2271
17. Asselin E., Mills G.B., and Tsang B.K. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 61 (2001) 1862-1868
18. Tamura M., Gu J., Takino T., and Yamada K.M. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res. 59 (1999) 442-449
19. Ishibashi T., and Lippard S.J. Telomere loss in cells treated with cisplatin. Proc. Natl. Acad. Sci. USA 95 (1998) 4219-4223
20. Battegay E.J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med. 73 (1995) 333-346
21. Sun H., Lesche R., Li D.M., Liliental J., Zhang H., Gao J., Gavrilova N., Mueller B., Liu X., and Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA 96 (1999) 6199-6204
22. Persad S., Attwell S., Gray V., Delcommenne M., Troussard A., Sanghera J., and Dedhar S. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc. Natl. Acad. Sci. USA 97 (2000) 3207-3212
23. Sima N., Wang S., Wang W., Kong D., Xu Q., Tian X., Luo A., Zhou J., Xu G., Meng L., Lu Y., and Ma D. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol. Oncol. 106 (2007) 299-304
24. Wu S., Meng L., Wang S., Wang W., Xi L., Tian X., Chen G., Wu Y., Zhou J., Xu G., Lu Y., and Ma D. Reversal of the malignant phenotype of cervical cancer CaSki cells through adeno-associated virus-mediated delivery of HPV16 E7 antisense RNA. Clin. Cancer Res. 12 (2006) 2032-2037
25. Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., Hemmings B.A., Wigler M.H., Downes C.P., and Tonks N.K. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc. Natl. Acad. Sci. USA 95 (1998) 13513-13518
26. Zhao L., Xu G., Zhou J., Xing H., Wang S., Wu M., Lu Y.P., and Ma D. The effect of RhoA on human umbilical vein endothelial cell migration and angiogenesis in vitro. Oncol. Rep. 15 (2006) 1147-1152
27. Nicosia S.V., Bai W., Cheng J.Q., Coppola D., and Kruk P.A. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol. Oncol. Clin. North Am. 17 (2003) 927-943
28. Di Cristofano A., and Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 100 (2000) 387-390
29. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 96 (1999) 4240-4245
30. Yan X., Fraser M., Qiu Q., and Tsang B.K. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol. Oncol. 102 (2006) 348-355
31. Jimenez C., Portela R.A., Mellado M., Rodriguez-Frade J.M., Collard J., Serrano A., Martinez A.C., Avila J., and Carrera A.C. Role of the PI3K regulatory subunit in the control of actin organization and cell migration. J. Cell Biol. 151 (2000) 249-262
32. Koul D., Parthasarathy R., Shen R., Davies M.A., Jasser S.A., Chintala S.K., Rao J.S., Sun Y., Benvenisite E.N., Liu T.J., and Yung W.K. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20 (2001) 6669-6678
33. Park M.J., Kim M.S., Park I.C., Kang H.S., Yoo H., Park S.H., Rhee C.H., Hong S.I., and Lee S.H. PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res. 62 (2002) 6318-6322
34. Sein T.T., Thant A.A., Hiraiwa Y., Amin A.R., Sohara Y., Liu Y., Matsuda S., Yamamoto T., and Hamaguchi M. A role for FAK in the Concanavalin A-dependent secretion of matrix metalloproteinase-2 and -9. Oncogene 19 (2000) 5539-5542